Between 1965 and 1974, two of us (JBC and DJW) worked in the Nuffield Institute of Medical Genetics, Department of Medicine, University of Liverpool. Cyril Clarke, then its director, allowed us to continue our studies of haemoglobin synthesis in thalassaemia which we had started together in the USA. At the time he, like many of our colleagues, may well have wondered about our sanity in pursuing research into what must have seemed a rather exotic group of anaemias of little obvious relevance to clinical practice in the UK. If he did he certainly never let us know, and he encouraged our efforts in every way possible. Because one of the first practical applications of this work was for the prenatal diagnosis of the common haemoglobin disorders we thought that an assessment of the current state of this important clinical problem might be an appropriate way of expressing our thanks for Cyril's scientific support and friendship over many years.
Background
The inherited disorders of haemoglobin are the commonest single gene diseases and cause a major public health problem in many parts of the world.'
As the high neonatal and childhood death rates due to infection and malnutrition in the developing countries are controlled, these conditions will create an even greater drain on health resources. For this Received for publication 10 June 1985. Accepted for publication 17 June 1985. reason many countries are, or are considering, developing prenatal diagnosis programmes for the prevention of the important haemoglobin disorders, particularly sickle cell anaemia, j3 thalassaemia, some forms of a thalassaemia, and disorders which result from the interaction of structural haemoglobin variants and thalassaemia, notably sickle cell or haemoglobin E-,6 thalassaemia.
The first attempts at prenatal diagnosis of the haemoglobin disorders made use of fetal blood sampling and in vitro globin chain mutation, the T--C change at position 6 of IVS-1 in Recently we have carried out another feasibility the 13 globin gene,30 had been analysed by oligonucstudy in two Mediterranean populations using oligo-leotide probe hybridisation the success rate would nucleotide probes that identify the commonest only have been increased to 75%; there was still a mutations in these countries, that is, the IVS-1 110 significant number of cases who, because they had at and the 1339 nonsense mutations.23 This study also least one rare 1 thalassaemia mutation, could not included an analysis of the RFLP haplotypes associ-have been identified by oligonucleotide probe analyated with the 13 thalassaemia mutations in each sis using a limited number of probes. family. Twenty families from the UK resident Cypriot population and 16 families from Milan were Implications for the future development of prenatal studied. The results suggest that prenatal diagnosis diagnosis programmes for the common haemoglobin of 13 thalassaemia would have been feasible in 65% disorders of Cypriots using oligonucleotide probes for the IVS-1 110 mutation and in 75% of Italians using There is no doubt from the recent summary of the 
use of fetal blood sampling and globin chain synthesis for prenatal diagnosis of the common haemoglobin disorders2 that this approach is extremely reliable. It has the advantage that it measures directly the product of the mutant gene, the ideal way of identifying a genetic disorder. However, because it can only be carried out late in the second trimester it carries the major disadvantage of a long wait for the mother and a potentially difficult termination. Thus it cannot be the long term answer to the prenatal diagnosis of these disorders. There is now enough published experience of direct DNA analysis, using either amniotic fluid cells or CVS, to be certain that this approach is an extremely valuable alternative to fetal blood sampling. Until the results of current trials are known, it is still too early to be certain whether CVS will replace amniocentesis in the long term.
The recent feasibility studies using one or two oligonucleotide probes for the common mutations in Mediterranean populations suggest that it will be possible to establish a reliable prenatal diagnosis in only about 60 to 70% of first pregnancies. This is because of the distribution of fi thalassaemia mutations, which seem to be similar in most populations. Thus, it appears that in every country in which this disorder is common there are a few very common mutations and a variable number of rare ones.8 31 32 This means that in every population a proportion of all seriously affected children will be compound heterozygotes, often for one of the common mutations and a rare one. Thus, in order to cover all eventualities it will be necessary to sequence many P thalassaemia genes and construct large numbers of oligonucleotide probes. Although oligonucleotide probe technology will improve and rapid sequencing methods are already available, it seems unlikely that it will be feasible to mount a massive operation of this kind in every high risk population in the immediate future.
These problems, which reflect mainly the heterogeneity of 13 Given all these uncertainties, and the rapid speed of development and change in the technology of DNA analysis, what is the best current approach to developing a reasonably comprehensive service for prenatal diagnosis of the common haemoglobin disorders? Obviously, in centres in which adequate screening and obstetric facilities exist, and where both haemoglobin synthesis and DNA analysis technology are fully developed, it is now possible to achieve close to 100% success rate for the prenatal diagnosis of these disorders using oligonucleotide probe or RFLP analysis or both, backed up by fetal blood sampling and globin chain synthesis for the relatively few cases in which a diagnosis by direct DNA analysis is impossible.
Thus, for the time being it will be necessary to use a combination of approaches to run a comprehensive prenatal diagnostic service. Since the ultimate aim is simplicity, further attempts should be made to find enzymes which will identify individual 13 thalassaemia mutations directly or RFLPs which are capable of clearly distinguishing thalassaemic from normal chromosomes in particular populations. The evolution of the prenatal diagnosis programme in Sardinia is a good example of how this field might progress. It started with globin chain synthesis studies and moved to RFLP linkage and oligonucleotide probe analysis; now, since a restriction enzyme has been discovered which is capable of diagnosing the majority of cases of thalassaemia in the population, it should be possible to use this relatively simple approach for most cases. However, there are few populations like Sardinia, in which a single mutation is found in the majority of cases, and in most countries it will be necessary to use a multi-pronged approach, at least for the forseeable future.
And what of countries which are considering setting up a comprehensive prenatal diagnosis programme de novo? First, a screening programme must be developed and the appropriate obstetric expertise obtained for fetal blood sampling, amniocentesis, and CVS. The necessary skills for DNA analysis should be developed at the same time. The next step will be to determine the common 13 thalassaemia mutations in the population. While this is being done, a limited programme could be developed using fetal blood sampling and RFLP analysis. The most simple approach to identifying the common 13 thalassaemia mutations in a particular population is to analyse the RFLP haplotypes; as mentioned earlier, specific mutations are usually associated with a particular haplotype. 9 Current experience suggests that in each population there will be one or two common 13 thalassaemia mutations. When the haplotypes have been analysed it should be possible to work out the molecular basis for the related 13 thalassaemias using either oligonucleotide probes or by sequencing the 13 globin genes. Since the latter is still a sophisticated and time consuming procedure it may be necessary to set up one or more central laboratories, possibly WHO designated, to carry out this work. Once the mutations have been defined it should be feasible to set up a comprehensive prenatal diagnosis service. A limited number of oligonucleotide probes should be synthesised to detect the common mutations. Prenatal diagnosis in first pregnancies should be carried out using these probes or fetal blood sampling; in subsequent pregnancies it should be possible to use oligonucleotide probes or RFLP analysis or both. In each population it will be very important to search for RFLPs which may distinguish thalassaemic from normal chromosomes and, in particular, for restriction enzymes which are capable of identifying the common mutations.
In summary, a country wishing to set up a comprehensive prenatal diagnosis programme for the haemoglobin disorders should develop a competent screening, obstetric, and genetic counselling service, backed up by a well planned approach to educate the public and health administrators about the diseases and why they should be prevented. At the same time laboratory expertise in globin chain synthesis and DNA analysis should be developed, and the common 13 thalassaemia mutations in the community should be defined. Until prenatal diagnosis by DNA analysis is feasible for every case, it will be necessary to retain the necessary skill for globin chain analysis. 
